SIRIO(SZ:300791) Xin Lang Cai Jing·2026-01-30 08:43Core Viewpoint - The company has released its 2025 earnings forecast and 2026 incentive plans, indicating a significant decline in expected profits due to asset impairment provisions related to BFPC and Hubei Yibenhui investments [1] Earnings Forecast - The company anticipates a net profit attributable to shareholders of between 101 million to 151 million yuan for 2025, representing a year-on-year decline of 68.85% to 53.44% [1] - The non-recurring net profit is expected to be between 58 million to 86 million yuan, reflecting a year-on-year decrease of 82.45% to 73.77% [1] - The impairments are primarily due to the full provision of 195 million yuan for the BFPC subsidiary and a 56.54 million yuan impairment for Hubei Yibenhui, which will not significantly impact cash flow [2] Incentive Plans - The company has introduced a restricted stock incentive plan for 2026, granting 2.2025 million shares at a price of 12.21 yuan per share, covering 85 management and core technical personnel [1][3] - The revenue targets for unlocking the incentives from 2026 to 2028 are set at no less than 5.09 billion, 5.38 billion, and 5.83 billion yuan, respectively [1] - An employee stock ownership plan has been announced, with a total of up to 32.0575 million shares, covering no more than 12 core management members, with profit targets set at 380 million yuan for 2026 and 450 million yuan for 2027 [1][3] Business Strategy - The company plans to divest the non-synergistic personal care business BFPC, which will help focus on its core operations and improve profitability [2] - The company aims for stable high single-digit compound growth in revenue, with a broader incentive coverage and increased intensity [3] - The company is positioned to capture market share in the global nutrition and health food solutions industry, which is expected to grow significantly [4] Market Position - The global nutrition and health food solutions market is projected to grow from 29.4 billion USD in 2024 to 42.4 billion USD by 2029, with a compound annual growth rate of 7.6% [4] - The company ranks third globally with a market share of 2.0%, particularly strong in gummy and soft capsule segments [4] - The company is expected to benefit from trends such as market fragmentation and customer diversification, enhancing its competitive position [4] Financial Projections - The company has adjusted its profit forecasts for 2025 to 120 million yuan, 2026 to 380 million yuan, and 2027 to 460 million yuan, reflecting the impact of impairment provisions and incentive costs [6] - The price-to-earnings ratios are projected at 60, 19, and 16 times for 2025, 2026, and 2027, respectively [6] - The target price for 2027 is maintained at 32.5 yuan, with a strong buy rating [6]